Project 6
NTRK/ROS1/ALK fusion-positive advanced tumors
Phase IActive
Key Facts
Indication
NTRK/ROS1/ALK fusion-positive advanced tumors
Phase
Phase I
Status
Active
Company
About Suzhou Teligene
Clinical-stage Chinese biotech developing brain-penetrant small molecule targeted therapies for oncology, with multiple programs in Phase I-II trials.
View full company profile